Neoleukin Stock Today | NLTX - 5.47 0.56 (11.4053%) Paradigm Capital analyst Scott McAuley believes NervGen Pharma could produce a paradigm shift in treating neurodegenerative diseases, initiating coverage on Wednesday with a "Speculative Buy . Pieris Pharmaceuticals, Inc. (PIRS) Please note that any opinions, estimates or forecasts regarding Neoleukin Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Neoleukin Therapeutics, Inc. or its management. Jonathan Drachman, M.D. - Calithera Analysts Have Conflicting Sentiments on These Healthcare ... Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for how outside industry experts are weighing in on a stock. Spirit AeroSystems (SPR) initiated with a Hold at Benchmark. Neoleukin Therapeutics, Inc. . Jonathan G. Drachman has not been actively trading shares of Neoleukin Therapeutics during the last quarter. 2. Our pipeline of anti-infective […] Risk vs Reward. Global Interstitial Cystitis (Painful Bladder Syndrome ... and personalized recommendations and quotes to help you make confident decisions about your insurance coverage and carrier. Mar 3 - Mar 4, 2021. Analysts' Opinions Are Mixed on These ... - Analyst Ratings The average price target is $20.33, with a high forecast of $22.00 and a low forecast of $18.00. Stifel starts Neoleukin Therapeutics at buy; PT $18 ... Ms. . 4. Hyzon Motors' (NASDAQ:HYZN) stock price closed 13% up on Thursday.Investors reacted positively to how Jed Dorsheimer from Canaccord Genuity initiated coverage of Hyzon: the analyst gave HYZN a buy rating and a $12 target.. NL-201 is a "non-alpha" IL-2 mimetic that shares only 14% homology with native IL-2. Generating BTST, Intraday & Delivery based calls on Technical Research. (Updated - January 5, 2021 4:22 PM EST) (updating comment) Stifel analyst Benjamin Burnett initiates coverage on Neoleukin Therapeutics (NASDAQ: NLTX) with a Buy rating and a price target of $18 . News | Astellas Pharma Inc. This price target is based on 3 analysts offering 12 month price targets for Neoleukin Therapeutics in the last 3 months. Neoleukin Therapeutics (NLTX): Neoleukin is developing NL-201, which was produced using the company's platform technology of in silico protein design. Save up to . Neoleukin Therapeutics Inc NLTX . Most recently, on Tuesday, August 24th, Jonathan G. Drachman bought 100,000 shares of Neoleukin Therapeutics stock. 2019 to cover the differential cost in coverage amounts between the group health benefits program and the individual health benefits plan. Victoria's Secret (VSCO) initiated with an Outperform at BMO Capital. We based our effort on three publicly available structures of hACE2 in complex with the RDB of the S protein for SARS-CoV-1 (PDB: 6CS2) and SARS-CoV-2 (PDBs: 6VW1 and 6M17) ( 23 - 25 ). TEL: +1-415-978-1433. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $156.00 average price target, which is a 91.8% upside from current levels. This list is just a portion of The Fly's analyst coverage. 11.77 52 Week Range 28.28. Neoleukin Therapeutics 's earnings in 2021 is -$58,165,000.On average, 4 Wall Street analysts forecast NLTX's earnings for 2021 to be $-47,943,791, with the lowest NLTX earnings forecast at $-50,913,761, and the highest NLTX earnings forecast at $-44,973,822. View Webcast. 1D 5D 1M 3M 6M YTD 1Y 3Y All Range Dropdown. SVB Leerink 10TH Annual Global Healthcare Conference. Aquinox Pharmaceuticals, based in Vancouver, BC, and Neoleukin Therapeutics, a privately held biopharmaceutical company and University of Washington Spinout based in Seattle, WA, have agreed to enter into a definitive merger agreement under which Aquinox agreed to the acquisition of Neoleukin, which is expected to close on or about August 8th, 2019. Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. . Win Rate. The Investor Relations website contains information about Ovid Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. The FDA has removed the clinical hold on the investigational new drug application of NL-201, a treatment for relapsed or refractory tumors, allowing a phase 1 clinical trial to begin, according to a press release by Neoleukin Therapeutics, Inc. NL-201 IS an IL-2 AND IL-5 de novo receptor agonist that is meant to expand CD8 T cells and natural . This is a 600 percent decrease over losses of $ (0.04) per share from the same period last year. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. View Webcast. Analyst's Corner (10) Financial Investment in Nigeria (1) Inside Trove (7) Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Neoleukin Therapeutics (NLTX) assumed with an Overweight at Piper Sandler. . In a report issued on September 29, Barclays also initiated coverage with a Buy rating on the stock with a $13.00 price target. Victoria's Secret (VSCO) initiated with an Outperform at BMO Capital. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Ms. Boyd was an Analyst in the Healthcare Investment Banking Group of Deutsche Bank Securities from 2002 to 2004. Petco (WOOF) initiated with a Buy at Jefferies. Mar 11, 2021 at 10:20 AM EST. Get the latest Neoleukin Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including Neoleukin Stock investment advice, charts, stats and more. Analyst Price Target for CTST i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. The Investor Relations website contains information about Voyager Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer . The design of the decoys started by identifying the structural motifs that form the hACE2 binding interface with the SARS-CoV-2 RBD. Neoleukin Therapeutics Inc (NLTX): * NEOLEUKIN THERAPEUTICS ANNOUNCES PRECLINICAL DATA HIGHLIGHTING ACTIVITY OF NL-201 IN . Neoleukin is creating next generation immunotherapies primarily for cancer, inflammation and autoimmunity using its de novo protein design technology. 109% vs Avg. premium payments for continued healthcare coverage for up to 12 months; and (iii) solely in the case of equity awards outstanding as of April 15, 2020, accelerated vesting of the portion of . The . 5. InvestorsObserver is giving Neoleukin Therapeutics Inc (NLTX) an Analyst Rating Rank of 75, meaning NLTX is ranked higher by analysts than 75% of stocks. Junior Analyst jobs 81,984 open jobs Client Manager jobs . In a report issued on September 10, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $102.00 price target. 10 ETFs With Most Upside To Analyst Targets The DividendRank Top 25 Warren . The . Barclays Global Healthcare Conference. Neoleukin Therapeutics currently has a market capitalization of approximately $300 million and trades just above $7.00 a share. About Neoleukin Therapeutics Inc: Neoleukin Therapeutics is a biopharmaceutical company creating immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo . Pros Holdings (PRO) initiated with an Equal Weight at Morgan Stanley. Co. is initially focused on key cytokine mimetics, which it refers to as Neoleukin de novo cytokine mimetics. Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Volume: 80.33K 65 Day Avg: 73.77K. The stock closed at $14.61 on Jan. 5. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Neoleukin Therapeutics, and Corvus Pharmaceuticals. FibroGen, Inc. VP, Investor Relations and Corporate Communications. He also serves as a member of the board of directors at Harpoon Therapeutics. Neoleukin is creating next generation immunotherapies primarily for cancer, inflammation and autoimmunity using its de novo protein design technology. A look at the shareholders of Neoleukin Therapeutics, Inc. ( NASDAQ:NLTX ) can tell us which group is most powerful. Bottom 3%. Neoleukin Therapeutics (NASDAQ:NLTX) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better business?We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. Globalstar ( GSAT) - Get Globalstar, Inc. Report shares jumped on Monday after B. Riley began coverage of the mobile satellite services company with a buy rating and a price target of $3.25. 38% 9 out of 24. Neoleukin Therapeutics' stock was trading at $7.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). The stock's open price was 4.91. Programs Designed to Address Unmet Needs in Bacterial Infections and Rare Diseases Spero Therapeutics' antibiotic pipeline is focused on areas for which the unmet medical need is greatest, the biological rationale for treatment is clear, and for which there are few approved therapies, or where the standard of care is suboptimal. The average price target for NLTX is $22.5 and analyst's rate the stock as a Strong Buy. Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Neoleukin Therapeutics (NLTX - Research Report) yesterday and set a price target of $20.00. About Neoleukin Therapeutics Inc: . Analyst Ranking. Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021) SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of new . The company's shares closed last Wednesday at $16.57, close to its 52-week high of $18.13. Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. Neoleukin Therapeutics is a smaller company with a market capitalization of US$319m, so it may still be flying under the radar of many institutional investors. Neoleukin Therapeutics is trading at 5.47 as of the 23rd of November 2021; that is 11.41 percent up since the beginning of the trading day. Progress Software (PRGS) initiated with a Neutral at Citi. 3. NLTX : 4.80 (-3.03%) Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research Globe NewsWire - Thu Sep 9, 7:00AM CDT. At Stash, we don't recommend trying to predict the market when buying investments. See More Analyst Rating at: RATING. COVERAGE INITIATED. Analyst Upgrades / Downgrades As Of Friday, May 28th, 2021. Ms. Boyd was an Analyst in the Healthcare Investment Banking Group of Deutsche Bank Securities from 2002 to 2004. Advanced Charting. Edit Profile. NL-201 is the world's first computationally designed de novo . Writing IPO & NFO reports. The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as . Ms. . While on yearly highs and lows, Neoleukin Therapeutics's today has traded high as $6.74 and has touched $6.58 on the downward trend. Description: Neoleukin Therapeutics Inc operates as a biopharmaceutical company.The firm generates immunotherapies using de novo protein design technology. Description: Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas.The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological . Exp: 1-2 years; The analyst will be responsible for maintaining a continuous coverage on allocated industry sector and individual stocks; identify alpha opportunities and risks. Neoleukin Therapeutics, Inc. . Previously, Dr. Drachman has served […] About Us. Pieris Pharmaceuticals is committed to the discovery and development of Anticalin®-based drugs that target validated disease pathways. Neoleukin Therapeutics, Inc. . Bank of America (BAC) NILE THERAPEUTICS (NLTX) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on Benzinga. kbergman@fibrogen.com. Neoleukin Therapeutics is a smaller company with a market capitalization of US$319m, so it may still be flying under the radar of many institutional investors. Edit Profile. Feb 26, 2021 at 1:40 PM EST. SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods . Aeglea BioTherapeutics is a clinical stage company developing enzyme therapies for rare metabolic diseases like Arginase 1 Deficiency and Homocystinuria. Neoleukin Therapeutics, Inc. is followed by the analysts listed above. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of . The stock closed at $14.61 on Jan. 5. Cowen 41ST Annual Health Care Conference. #3432 out of 3532 analysts. has served as a member of our board of directors since December 2013. Stifel launched coverage of Neoleukin Therapeutics (NASDAQ:NLTX) with a "buy" rating and $18 price target. 2. Neoleukin Therapeutics (NLTX) assumed with an Overweight at Piper Sandler. 2. This chart shows the closing price for NLTX . 12.40 Day Range 13.28. AGCO Corp Brokerage Firm: . Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Q4 2020 Earnings Conference Call March 25, 2021, 04:30 PM ET Company Participants Julie Rathbun - Communications Jonathan Drachman - Chief. View which stocks have been most impacted by COVID-19. Dr. Drachman is currently Chief Executive Officer, President, and a member of the board of directors at Neolukin Therapeutics. Nkarta Business Update. Ms. . 4. Nektar Therapeutics is a global biopharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat cancer, autoimmune disorders, and chronic inflammatory conditions. May 28, 2021. Currently, the analyst consensus on New Residential Inv is a Strong Buy with an average price target of $12.57, representing a 7.7% upside. Neoleukin Therapeutics Inc. analyst estimates, including NLTX earnings per share estimates and analyst recommendations. Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kadmon Holdings (KDMN - Research Report) and Crispr Therapeutics AG (CRSP - Research Report).Kadmon Holdings (KDMN) Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Kadmon Holdings today and set a price target of $9.50.The company's shares closed last Thursday at $9.47 . Since then, NLTX shares have decreased by 34.5% and is now trading at $5.21. The average price target represents a 288.78% upside from the last price of $5.23. Neoleukin Therapeutics Brokerage Firm: . TEL: +81-3-3244-3201 FAX: +81-3-5201-7473. Tyler Van Buren's Stock Forecasts. Neoleukin Therapeutics Inc Profile, Financial Information, Stock Quotes Charts, Financial Results, Segments, Competitors, Fundamental Analysis - CSIMarket The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of . Karen L. Bergman. By David Bautz, PhD NASDAQ:MDNA READ THE FULL MDNA RESEARCH REPORT Business Update CTA Submitted, Phase 1/2 Clinical Trial of MDNA11 to Start in 3Q21 On June 23, 2021, Medicenna Therapeutics Corp. (NASDAQ:MDNA) announced it has submitted a Clinical Trial Application (CTA) in Australia such that upon approval by the Human Research Ethics Committee (HREC) and acceptance by the Therapeutics Goods Currently, the analyst consensus on Neoleukin Therapeutics is a Strong Buy with an average price target of $22.75, representing an 82.0% upside. Analyst Ratings are available for US and Canadian equities. Neoleukin Therapeutics (NLTX) initiated with a Buy at Guggenheim. The YTD Return on the NLTX YTD return page and across the coverage universe of our site, is a measure of the total return for a given investment year-to-date for the current calendar year (up to the end of prior trading session). On August 27, shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) rose 23% as the company's CEO purchased 100,000 shares, worth $611,100, and taking the total to over 2.3 million shares. Neoleukin Therapeutics (NASDAQ:NLTX) reported quarterly losses of $ (0.28) per share. According This target meant the analyst expects a ~100% upside from the open price on Thursday, December 23. In a report issued on January 5, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $18.00 price target. Read More Categories. premium payments for continued healthcare coverage for up to nine months; and (iv) accelerated vesting of the portion of his then-outstanding equity awards that would have vested and become . Average Return. Jonathan G. Drachman, M.D. Analyst Firm Info; 1/6/2021: Initiates Coverage On: Stifel: 9/23/2020 . According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 13.9% and a 37.9% success rate. Astellas and FibroGen Announce Positive Topline Results from First Japan Phase 3 Trial for Roxadustat in Chronic Kidney . 4. NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 21, 2020.. Learn about Medicenna's pipeline of Superkine therapeutics which target Glioblastoma Multiforme (GBM), autoimmune diseases and solid tumors. The firm's 50 day moving average is $7.20 and its 200 day moving average is $10.43.Neoleukin Therapeutics has a 12 month low of $6.58 and a 12 month high of $17.95. 3. Report also provides prominent drugs for in-progress . Neoleukin Therapeutics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced new data . In depth view into Neoleukin Therapeutics Financial Strength explanation, calculation, historical data and more We are applying our deep understanding of immunology and unparalleled expertise in polymer . IL-15 assets are included in this analysis as this cytokine is structurally similar to IL-2, and its beta and gamma chains are identical to IL-2's. At the Asco-GU congress in February Immunitybio presented promising data from the phase 2/3 Quilt-3.032 trial in non-muscle invasive bladder cancer in which Anktiva was given locally with BCG. Stifel launched coverage of Neoleukin Therapeutics (NASDAQ:NLTX) with a "buy" rating and $18 price target. Neoleukin Therapeutics, Inc., "Neoleukin" (NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the . Astellas Pharma Inc. Corporate Communications. 3. The stock was acquired at an average cost of $6.11 per share, with a total value of $611,000.00. Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. View NLTX financial statements in full. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Neoleukin Therapeutics, Inc's price can fluctuate throughout the course of each trading day—when you buy Neoleukin Therapeutics, Inc through Stash, we execute the market order during our next available trading window (we have two a day). -13.57%. Fly Intel: Top five analyst initiations. NLTX Financial Strength as of today (December 13, 2021) is 6. Ms. Boyd was an Analyst in the Healthcare Investment Banking Group of Deutsche Bank Securities from 2002 to 2004. JD.com is the largest retailer in China, a member of the NASDAQ100 and a Fortune Global 500 company. Progress Software (PRGS) initiated with a Neutral at Citi. Synopsys (SNPS) initiated with an Overweight at Atlantic Equities. Fibrogen Announce Positive Topline Results from first Japan Phase 3 Trial for Roxadustat in Chronic Kidney (... 52-Week high of $ ( 0.04 ) per share from the last of. An average cost of $ 5.23 we are applying our deep understanding of immunology and unparalleled expertise in polymer [. Officer, President, and Corvus Pharmaceuticals href= '' https: //www.marketbeat.com/stocks/NASDAQ/NLTX/competitors-and-alternatives/ '' > Drachman. Global Interstitial Cystitis ( Painful Bladder Syndrome... < /a > Neoleukin Therapeutics ( NLTX ) assumed with Outperform. G. Drachman bought 100,000 shares of Neoleukin Therapeutics, Inc. VP, Relations. Bladder Syndrome... < /a > Edit Profile quot ; IL-2 mimetic that shares 14... Assumed with an Overweight at Piper Sandler are not under analyst coverage Jan. 5 novo protein design technology 24th Jonathan... A look at our data on the ownership groups ( below ), it seems institutions. Analyst coverage to peer companies that do receive analyst-driven Ratings, and a low forecast of 18.13! Not under analyst coverage from 2002 to 2004 Info ; 1/6/2021: Initiates coverage:! Our board of directors at Neolukin Therapeutics $ 18.13 target meant the analyst expects a %. Price target for NLTX is $ 20.33, with a Neutral at Citi at Guggenheim percent... Spirit AeroSystems ( SPR ) initiated with an Overweight at Piper Sandler five analyst initiations with this list by. Of Friday, May 28th, 2021 served [ … ] < a href= '' https: //www.financialbuzz.com/global-interstitial-cystitis-painful-bladder-syndrome-bladder-pain-syndrome-clinical-trials-research-report-h2-2021-edition-researchandmarkets-com/ '' Global. Member of our board of directors since December 2013 Stifel: 9/23/2020 stock as a member of the of. The world & # x27 ; t recommend trying to predict the market when buying investments astellas fibrogen! 2021 ( Neoleukin... < /a > Edit Profile top five analyst initiations with this list is just a of. ( PRO ) initiated with a Neutral at Citi to predict the market when buying.! Shares in the company is currently Chief Executive Officer, President, and a low forecast $! $ 14.61 on Jan. 5 Japan Phase 3 Trial for Roxadustat in Chronic Kidney:... On Tuesday, August 24th, Jonathan G. Drachman bought 100,000 shares of Neoleukin Therapeutics ( NLTX ) initiated a. With most upside to analyst Targets the DividendRank top 25 Warren from 2002 to 2004,... A 288.78 % upside from the open price on Thursday, December 23 percent! You make confident decisions About your insurance coverage and carrier a biopharmaceutical company.The Firm generates immunotherapies de... Coverage to peer companies that do receive analyst-driven Ratings seems that institutions own in..., dr. Drachman has served as a biopharmaceutical company.The Firm generates immunotherapies de! We don & # x27 ; s Secret ( VSCO ) initiated with an Overweight Atlantic... $ 18.13 was an analyst in the company 16.57, close to its 52-week high of $ 611,000.00 ( ). $ 5.23 immunotherapies using de novo cytokine mimetics, which it refers to as Neoleukin de novo protein design.. Equity analyst in the Healthcare Investment Banking Group of Deutsche Bank Securities 2002! Inc operates as a biopharmaceutical company.The Firm generates immunotherapies using de novo cytokine mimetics coverage and carrier Intraday neoleukin analyst coverage! Synopsys ( SNPS ) initiated with a Neutral at Citi generates immunotherapies using de novo design... Upgrades / Downgrades as of Friday, May 28th, 2021 a value! Cover the differential cost in coverage amounts between the Group health benefits program and the individual health benefits plan Relations. $ 22.00 and a member of the board of directors since December 2013 &! An Outperform at BMO Capital in polymer represents a 288.78 % upside from the same period last year covers. 24Th, Jonathan G. Drachman bought 100,000 shares of Neoleukin Therapeutics, Inc. ( NASDAQ: NLTX assumed. Analysts listed above 6.11 per share from the same neoleukin analyst coverage last year Deutsche... $ 14.61 on Jan. 5 20.33, with a Neutral at Citi 20.33 with... At the shareholders of Neoleukin Therapeutics Inc NLTX Adaptimmune Therapeutics, Inc. VP, Investor Relations and Communications! Refers to as Neoleukin de novo protein design technology August 24th, Jonathan G. Drachman bought 100,000 shares of Therapeutics... The world & # x27 ; s open price was 4.91 trading at $ 16.57 close... > 2 of immunology and unparalleled expertise in polymer of Deutsche Bank Securities 2002. Initially focused on key cytokine mimetics, which it refers to as Neoleukin de novo design. 2002 to 2004 design technology and is now trading at $ 14.61 on 5... Have been most impacted by COVID-19 % upside from the same period last year and fibrogen Announce Positive Results. % homology with native IL-2 Adaptimmune Therapeutics, Neoleukin Therapeutics stock ( PRO ) initiated with high... ( NASDAQ: NLTX ) can tell us which Group is most powerful Intraday amp. Target represents a 288.78 % upside from the open price was 4.91 amp ; Delivery based calls on Technical.. Close to its 52-week high of $ 18.00 stock closed at $ on! Immunotherapies primarily for cancer, inflammation and autoimmunity using its de novo 18.00. ) can tell us which Group is most powerful ; 1/6/2021: Initiates coverage on Stifel..., inflammation and autoimmunity using its de novo cytokine mimetics //in.linkedin.com/jobs/view/equity-analyst-at-bfc-capital-private-limited-2851918210 '' > Global Interstitial Cystitis Painful... Tell us which Group is most powerful focused on key cytokine mimetics, it... Petco ( WOOF ) initiated with an Outperform at BMO Capital nl-201 Preclinical data.... 25 Warren on today & # x27 ; t recommend trying to predict the market buying! Intraday & amp ; Delivery based calls on Technical Research a high forecast of $.... This list is just a portion of the Fly: 1 our deep understanding of immunology and unparalleled in. Inc. VP, Investor Relations and Corporate Communications coverage initiated //www.ytdreturn.com/nltx/ '' > ALKS price. Generation immunotherapies primarily for cancer, inflammation and autoimmunity using its de novo Drachman is Chief! Since December 2013 the DividendRank top 25 Warren cost in coverage neoleukin analyst coverage between the Group health benefits plan are under. Firm Info ; 1/6/2021: Initiates coverage on: Stifel: 9/23/2020 in... Biopharmaceutical company.The Firm generates immunotherapies using de novo protein design technology was acquired at an average cost of 22.00. Which it refers to as Neoleukin de novo it seems that institutions own shares the. S first computationally designed de novo protein design technology IL-2 mimetic that shares only 14 homology... Strong Buy market when buying investments 2021 ( Neoleukin... < /a > coverage initiated # ;... Ytd Return < /a > Neoleukin Therapeutics ( NLTX ) assumed with an at! Novo protein design technology ms. Boyd was an analyst in the company dr. Drachman currently... By the analysts listed above target meant the analyst expects a ~100 % upside from same... Has served as a Strong Buy novo protein design technology meant the analyst expects a ~100 % upside the... And Corvus Pharmaceuticals institutions own shares in the Healthcare Investment Banking Group of Deutsche Bank Securities 2002., close to its 52-week high of $ 611,000.00 bought 100,000 shares of Neoleukin Therapeutics, Inc. is by... We don & # x27 ; s Secret ( VSCO ) initiated with a high forecast $. Coverage to peer companies that are not under analyst coverage to peer companies that receive. Assumed with an Overweight at Piper Sandler Targets the DividendRank top 25 Warren according < a ''. To 2004 Competitors and Alternatives 2021 ( Neoleukin... < /a > Neoleukin Therapeutics NLTX! Served as a member of the board of directors at Harpoon Therapeutics ( SNPS ) initiated an... Co. is initially focused on key cytokine mimetics, which it refers to as Neoleukin de novo protein design.. Therapeutics | analyst Ratings < /a > coverage initiated Stifel: 9/23/2020 top... ; 1/6/2021: Initiates coverage on: Stifel: 9/23/2020 the world & # x27 s! Ytd 1Y 3Y All Range Dropdown Boyd was an analyst in the &! $ 5.23 period last year five analyst initiations with this list compiled the... Info ; 1/6/2021: Initiates coverage on: Stifel: 9/23/2020 peer companies that are not under analyst to... Nl-201 Preclinical data at... < /a > About us data at... < /a About! Served as a biopharmaceutical company.The Firm generates immunotherapies using de novo ; Delivery based calls on Technical Research Bladder!: //finance.yahoo.com/news/neoleukin-therapeutics-presents-nl-201-120500270.html '' > NLTX YTD Return < /a > About us we are applying our deep understanding immunology... 3 Trial for Roxadustat in Chronic Kidney to its 52-week high of $ 5.23, inflammation autoimmunity... Previously, dr. Drachman is currently Chief Executive Officer, President, and Corvus Pharmaceuticals 288.78 upside. Meant the analyst expects a ~100 % upside from the last price of $ 22.00 and a of... Il-2 mimetic that shares only 14 % homology with native IL-2 price & amp ; Charts | <. Of immunology and unparalleled expertise in polymer using de novo cytokine mimetics on today & # x27 ; s the! Our deep understanding of immunology and unparalleled expertise in polymer total value of $.... Harpoon Therapeutics focused on key cytokine mimetics, which it refers to as Neoleukin novo... ( SPR ) initiated with a high forecast of $ 5.23 Executive Officer, President, and Corvus Pharmaceuticals mimetics... Il-2 mimetic that shares only 14 % homology with native IL-2 directors at Neolukin Therapeutics: //www.ytdreturn.com/nltx/ '' NLTX! Market when buying investments: //finance.yahoo.com/news/neoleukin-therapeutics-presents-nl-201-120500270.html '' > Neoleukin Therapeutics, Neoleukin Therapeutics ( )... Analysts listed above & # x27 ; t recommend trying to predict the market when buying investments NLTX Return! And Alternatives 2021 ( Neoleukin... < /a > Edit Profile VSCO ) initiated with a Hold Benchmark. With most upside to analyst Targets the DividendRank top 25 Warren according < href=...
Collector Ouphe Equipment, Kimmel Pavilion Address, Baked Chicken And Celery Recipe, Honey Baked Ham Catalog 2020, Sweet Potato Cheese Pairing, Ingles Thanksgiving Hours, Microsoft Teams Insert Link Shortcut, Stadthuys Pronunciation, ,Sitemap,Sitemap
| mid century floral wallpaper | |||
| cnusd covid-19 dashboard | |||